Trail Ridge Investment Advisors LLC Invests $753,000 in The Cooper Companies, Inc. $COO

Trail Ridge Investment Advisors LLC acquired a new stake in The Cooper Companies, Inc. (NASDAQ:COO) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 10,500 shares of the medical device company’s stock, valued at approximately $753,000.

Several other large investors have also bought and sold shares of the company. Avalon Trust Co bought a new stake in Cooper Companies in the second quarter worth about $25,000. Root Financial Partners LLC lifted its holdings in Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 162 shares during the last quarter. SJS Investment Consulting Inc. boosted its position in shares of Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares in the last quarter. Elevation Wealth Partners LLC boosted its position in shares of Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares in the last quarter. Finally, J.Safra Asset Management Corp acquired a new position in shares of Cooper Companies in the 2nd quarter worth approximately $32,000. Institutional investors own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a report on Wednesday, May 27th. Mizuho set a $85.00 price target on shares of Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Robert W. Baird dropped their price target on Cooper Companies from $98.00 to $85.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. JPMorgan Chase & Co. cut their price objective on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a research report on Friday, June 5th. Finally, UBS Group assumed coverage on Cooper Companies in a research note on Tuesday, July 28th. They set a “neutral” rating and a $75.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $81.64.

Cooper Companies Price Performance

COO stock opened at $75.80 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. The Cooper Companies, Inc. has a one year low of $58.89 and a one year high of $89.83. The firm has a market capitalization of $14.78 billion, a PE ratio of 64.24, a P/E/G ratio of 1.99 and a beta of 0.83. The firm has a 50-day moving average of $72.09 and a two-hundred day moving average of $71.07.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.11. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period last year, the firm posted $0.96 earnings per share. The firm’s quarterly revenue was up 7.9% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. On average, analysts forecast that The Cooper Companies, Inc. will post 4.63 earnings per share for the current year.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.